📝 HIV_lipid_compatibility_note_2.mdTheme:

Lipid Compatibility and Lipid Droplet Architecture: Open Questions on Primate-to-Human Lentivirus Jumps

A discussion note with testable questions

Author: Andrew, an independent enquirer (not a virologist). Version 2, November 2026.

1. Purpose and status of this note

This note sets out a small group of conjectures about the lipids of HIV and its primate ancestor SIV, and about how the state of a cell's lipid stores might shape what happens when a virus meets it. It asks whether anyone has already tested them. It is written for readers who work on viral envelopes, membrane lipidomics, lipid droplets, primate immunology or HIV cure research.

Status. Everything here is conjecture. The ideas began in long exploratory conversations, including one with a general-purpose AI search assistant that agreed with everything I said and added claims I could not verify. I have since checked each literature claim against published sources and removed the ones I could not support. Please treat every statement as a question for specialists, and correct me where I am wrong. Sources are in section 11.

Glossary.

Term	Meaning
SIV	Simian immunodeficiency virus, the primate relatives of HIV
Envelope	The lipid skin around the virus, taken from the host cell when the virus buds off
CD1d	A cell-surface molecule that shows lipids to a type of immune cell (iNKT cells, a kind of natural killer T cell)
Nef, Vpu	HIV accessory proteins that interfere with host defences
25HC	25-hydroxycholesterol, a modified cholesterol made by the enzyme CH25H
Lipid droplet	A cell's fat-storage organelle: a core of neutral fats wrapped in a single layer of phospholipid and proteins
ApoE	A lipid-carrier protein, central to brain lipid transport
Astrocyte	A support cell of the brain

2. The core conjectures

HIV's envelope is host membrane. I conjecture three things:

Subset hypothesis. SIV's envelope lipid profile may be close to a subset of what human cells can supply, so the virus finds a compatible lipid environment on crossing into humans.
Incompatibility hypothesis. Where a lentivirus fails to cross into a new species ("wrong host"), part of the reason may be that the new host cannot supply a lipid environment the virus's proteins need.
Lipid droplet architecture. Neighbouring cells with identical DNA differ in the number, size, position and contents of their lipid droplets. This state could help decide how each cell responds to infection, including how much virus it makes or whether it goes latent.

I do not claim lipids are the main barrier. The best-documented barriers are protein-level (section 4). The question is whether lipid state is a contributing, under-measured factor.

3. What is established about HIV envelope lipids

The envelope comes from the host. HIV buds from the host plasma membrane at raft-type sites (Brügger 2006; Scientific Reports 2016).
It is not a plain copy of the host membrane. Mass spectrometry shows the virus is enriched in cholesterol and sphingomyelin, and its overall composition resembles detergent-resistant membrane domains and is strikingly different from the producer cells' membranes (Brügger 2006).
The virus can shift its own lipid makeup. The presence of Nef during virus production raised sphingomyelin and lowered polyunsaturated phosphatidylcholine in virions, without a significant change in cholesterol (Brügger 2007). The authors found these changes insufficient to explain Nef's effect on infectivity.
Envelope lipids matter for infection. Removing cholesterol from the virion reduces its ability to fuse with cells (PubMed 12239312; PMC516414).

Consequence for the subset hypothesis. Because the virus actively selects a raft-like composition, the sharper question is not "is SIV's lipid profile a subset of human lipids?" but "can a human producer cell, and a human target cell, supply and respond to the specific raft-like environment SIV's proteins evolved to use?"

4. What is established about cross-species barriers

The well-documented barriers are host restriction factors, which are cell proteins that block viral replication, and the viral proteins that counter them:

Crossing between primate species required viral adaptation to restriction factors such as APOBEC3 (review; APOBEC3G and SIVmac).
The chimpanzee ancestor of pandemic HIV-1 switched from Nef to Vpu to counter human tetherin (PLoS Pathogens 2009; Cell Host Microbe 2012).

These are protein-level explanations. I have not found a study that tests lipid compatibility as a separate barrier. That is the gap this note points at, and I may have missed work that fills it.

5. A known lipid-based antiviral route (prior art)

I arrived at the idea of changing host lipids to block entry independently, and later found it is an active field:

Interferon induces the enzyme CH25H, which makes 25HC. 25HC blocks membrane fusion by many enveloped viruses, including HIV. In humanized mice it suppressed HIV and reversed T-cell depletion, though it is hard to deliver in large doses (Liu et al., Immunity 2013; UCLA summary).
Model-membrane work shows 25HC halves liposome fusion compared with cholesterol and alters the conformation of the HIV fusion peptide (Gomes et al., 2018).

Limits of this route. A single lipid change is not a permanent lockout. Cells keep making their own lipids, the virus can adapt, and because the envelope is host-made, anything that changes it also acts on healthy cells. The practical obstacle is collateral damage, which is why this has not become a mainstream treatment.

6. Second conjecture: primate CD1d and Nef

CD1d presents lipid antigens to iNKT cells. HIV-1 Nef and Vpu reduce CD1d at the cell surface. Nef does it by increasing internalisation and holding CD1d in the trans-Golgi network, and this depends on a tyrosine-based motif in CD1d's cytoplasmic tail (Chen et al., 2006; Vpu and Nef review). Vpu from some HIV-1 group N strains is largely unable to do this (NCBI gene summary).

My question. Do primate versions of CD1d differ in a way that matters for Nef and Vpu, and could that explain, or be copied to produce, a CD1d that HIV cannot suppress?

What the literature says so far.

Function is highly conserved. Rhesus macaque iNKT cells bind and respond to human CD1d loaded with the standard lipid α-galactosylceramide (Yu et al.).
A 2025 preprint reports the first macaque CD1d structure and finds a difference at one groove-capping residue (Phe84, fixed in macaque, flexible in human) alongside a conserved gating mechanism (Burns et al., preprint). That is a lipid-binding difference, not a Nef-binding one.
Whether macaque or natural-host CD1d is resistant to SIV or HIV Nef and Vpu is, as far as I can find, not established. An AI answer I received claimed a specific human-versus-macaque difference in the cytoplasmic tail that blocks Nef. I could not confirm it, and I have not used it.

7. Third conjecture: lessons from natural hosts

African natural hosts of SIV, including sooty mangabeys, African green monkeys and mandrills, carry high viral loads without disease. The best-supported difference from HIV in humans is that they avoid chronic immune activation. They mount a strong early response and then actively dampen it (JCI commentary; mandrill study; Pasteur chapter). African green monkeys also show low CCR5 on CD4 cells, and low target-cell availability limits transmission to infants (PMC4019088).

My question. Is there a lipid or membrane component to how natural hosts dampen this response, and could copying natural-host tolerance be more productive than swapping individual molecules?

8. Fourth conjecture: lipid droplet architecture

8.1 The idea

Two neighbouring cells of the same type carry the same genes, yet they can respond differently to the same stimulus. Gene activity and metabolic state are the usual explanations. I conjecture that the arrangement of a cell's lipid droplets (how many, how large, where they sit, what they hold, and how they connect to membranes and mitochondria) is a working part of that state, and not only a fuel store. If so, it could influence how a cell handles infection.

8.2 What is established

Lipid droplets are already known to be more than fat stores, in settings close to this idea:

Neurons offload toxic lipids into glial droplets. Fatty acids damaged by oxidation in hyperactive neurons are passed to astrocytes in ApoE-carrying lipid particles and stored in astrocytic droplets. Astrocytes then burn them in mitochondria in response to neuronal activity and switch on a detoxification gene programme (Ioannou et al., Cell 2019). The point for this note is that a brain cell's lipid handling serves protection and regulation, not calorie balance. The brain has no bulk-storage problem to solve.
Droplets take part in antiviral defence. The interferon-induced antiviral protein viperin localises to lipid droplets, and hepatitis C virus uses droplets for assembly (Hinson and Cresswell, PNAS 2009; viperin and HCV). Zika and dengue infection induce droplets within hours, and loss of droplet mass weakens the response to Sendai virus (Viruses 2023).
Droplets hold immune proteins beyond viruses. In fruit-fly embryos, droplet-bound histones help kill bacteria (Current Biology 2015 review).

8.3 What is conjecture

That droplet architecture, as a pattern across a cell, is a main source of cell-to-cell difference in response, and not just a marker of it.
That it matters for HIV, for example in why some infected CD4 cells produce virus and others go latent. That is an open problem, and I am only asking whether droplet state belongs on the list of candidates.
I have not surveyed the HIV-specific droplet literature and expect others have worked on parts of this.

8.4 Where HIV and the droplet idea meet

The envelope is built from lipids the cell chooses to supply at the budding site. If droplet and membrane state differ between producer cells, the virions they make may differ in lipid makeup, and so in infectivity, even for the same virus genome. The experiments in section 10 test this directly.

9. Wider context: composition as information

A related idea has a respectable precedent in origin-of-life work and need not be accepted for the HIV questions above.

Compositional inheritance. The "Lipid World" proposal holds that self-assembling lipid assemblies can pass on information through their composition, with no genetic sequence, in a way analogous to non-genetic inheritance in modern cells (Segré et al., 2001; Weizmann group overview). The evidence is largely from simulation, and I have not checked the critiques.
RNA and lipids interact. Bulk RNA does not dissolve in fats, but RNA binds lipid membrane surfaces in a sequence-dependent way (guanine-rich sequences bind best), and that binding can change the activity of RNA enzymes (Czerniak and Sáenz, PNAS 2022; review, RNA Biology 2025).

I mention these because they show that "lipid state carries information" is a live scientific idea, not a fringe one. I make no claim that droplets predate genes. The relevant early structures would be lipid assemblies in general, and droplets are a particular modern organelle.

10. Proposed experiments (my suggestions, for specialists to improve or reject)

Comparative envelope lipidomics. Produce SIV (for example SIVcpz or SIVsmm) and HIV-1 in matched primate and human CD4 T cells and macrophages. Measure lipids of the virions and of the producer plasma membrane by mass spectrometry, following Brügger 2006. Test whether the virion profile is conserved across hosts or follows the host.
Does producer-cell lipid supply limit cross-species infectivity? Alter sphingomyelin, cholesterol or desaturation in producer cells, or use 25HC, and compare virion infectivity on primate and human target cells.
CD1d tail swap. Express human CD1d with a primate cytoplasmic tail (and the reverse) in human cells, then test Nef and Vpu downregulation and iNKT activation.
Droplet heterogeneity and infection outcome. Image lipid droplets in single primary CD4 T cells and macrophages, then follow the same cells after infection. Ask whether droplet state before infection predicts virus output, latency or death.
Droplet perturbation. Reduce or increase droplet formation in producer and target cells and measure virion lipid makeup and infectivity.

11. Ideas I have dropped

Dropped claim	Why
A single lipid change can lock HIV out of a cell for good	Lipid balance is actively maintained and the virus adapts.
Lipid targeting is a "holy grail" because the virus cannot mutate around it	Overstated. HIV adapts, and the envelope is host-made.
A specific macaque CD1d difference stops Nef, and gene-edited CD1d is in 2026 trials	Not supported by anything I could find.
Making HIV a harmless "companion" of HERV as a treatment	Becoming a permanent genome resident takes germline infection over very long timescales.
"Conventional wisdom says neighbouring cells are identical"	A strawman. Cells with identical DNA differ, and the open question is how much droplet state contributes.
"Neural adipocytes" and a fat-based heating grid for the nervous system	Adult brain has no true fat cells, adults have little brown fat, and nerve temperature is not held constant by it.
Droplets as the only store of memory	Published work treats astrocytic droplets as maintenance and protection. This note makes no memory claim.
Slogans such as "lipids are death"	Lipids build every cell membrane.

On HERVs. Human endogenous retroviruses, ancient retroviral sequences now inside our genome, are background only. Some were put to use (the placental protein syncytin is the best-known case), which shapes how I think about retroviruses as functional rather than purely harmful. They are not central to the questions above.

A broader body of work. I hold a wider, separate set of ideas on lipid droplets in the brain. It is deliberately left out here, so that this note stands on the HIV and droplet questions alone.

12. Sources

Brügger B et al. The HIV lipidome: a raft with an unusual composition. PNAS 2006. https://pmc.ncbi.nlm.nih.gov/articles/PMC1413831
Brügger B et al. HIV-1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology 2007. https://link.springer.com/content/pdf/10.1186/1742-4690-4-70.pdf
Functional organization of the HIV lipid envelope. Sci Rep 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC5039752
Cholesterol in the HIV-1 membrane and fusion. https://pubmed.ncbi.nlm.nih.gov/12239312; also https://pmc.ncbi.nlm.nih.gov/articles/PMC516414
Liu S-Y et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013. https://sigmaaldrich.com/PL/pl/tech-docs/paper/303783
Gomes B et al. Effect of 25-hydroxycholesterol in viral membrane fusion: insights on HIV inhibition. BBA Biomembranes 2018. https://ri.conicet.gov.ar/handle/11336/94246
Chen N et al. HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol 2006. https://bvbvf1.bib-bvb.de/vufind/PrimoRecord/cdi_proquest_miscellaneous_67633308
HIV-1 Vpu and Nef interfere with CD1d-mediated antigen presentation. https://pmc.ncbi.nlm.nih.gov/articles/PMC3412205
Yu KKQ et al. Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates. https://rcastoragev2.blob.core.windows.net/eb00501d32ea11ab21dda99016abba04/PMC6647187.pdf
Burns D et al. Ligand-responsive groove remodelling in human and macaque CD1d (preprint, Dec 2025). https://eprints.soton.ac.uk/510758/
APOBEC3 and cross-species transmission of SIV (review). https://pmc.ncbi.nlm.nih.gov/articles/PMC8228377
APOBEC3G polymorphism as a barrier to cross-species transmission. https://pmc.ncbi.nlm.nih.gov/articles/PMC3789815
Species-specific activity of SIV Nef and HIV-1 Vpu against tetherin. PLoS Pathog 2009. https://pmc.ncbi.nlm.nih.gov/articles/PMC2673686
Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. https://pmc.ncbi.nlm.nih.gov/articles/PMC3444822
Natural-host SIV infection and immune activation. JCI. https://jci.org/articles/view/41509; https://pmc.ncbi.nlm.nih.gov/articles/PMC3233116; https://research.pasteur.fr/en/b/BTs; https://pmc.ncbi.nlm.nih.gov/articles/PMC4019088
Ioannou MS et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell 2019. doi:10.1016/j.cell.2019.04.001. Summary: https://neurosciencenews.com/neuroprotection-astrocytes-14141/
Hinson ER, Cresswell P. The antiviral protein, viperin, localizes to lipid droplets via its N-terminal amphipathic α-helix. PNAS 2009. https://doi.org/10.1073/pnas.0911679106; Helbig K et al. The antiviral protein viperin inhibits HCV replication via interaction with NS5A. https://pmc.ncbi.nlm.nih.gov/articles/PMC3207276
Global lipidome profiling revealed multifaceted role of lipid species in hepatitis C virus replication, assembly, and host antiviral response. Viruses 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965260
Lipid droplets and pathogens (Current Biology 2015 review). https://pmc.ncbi.nlm.nih.gov/articles/PMC4452895
Segré D, Ben-Eli D, Deamer DW, Lancet D. The lipid world. Orig Life Evol Biosph 2001. https://link.springer.com/content/pdf/10.1023/A:1006746807104.pdf; Weizmann group overview: https://www.weizmann.ac.il/molgen/Lancet/research-activities/systems-protobiology
Czerniak T, Sáenz JP. Lipid membranes modulate the activity of RNA through sequence-dependent interactions. PNAS 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8794826; and The secret life of RNA and lipids. RNA Biology 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269668/

Links were located by web search in November 2026. I read abstracts and summaries, not every full text, so please check details against the originals.